UPDATE: Exact Sciences Posts 17 Percent Q4 Revenue Increase

Revenues for the quarter and year were comprised almost entirely of licensing fees and royalties as the firm prepares a trial for its Cologuard stool-based colorectal cancer screening test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.